Challenbio

About Challenbio

Beijing Challen Biotechnology Co., Ltd., operating as Challenbio, is a biotechnology firm established in March 2020. The company is headquartered in the Zhongguancun Science and Technology Park in Beijing, a hub for the biomedical industry. Challenbio specializes in the development, production, and sale of biomedical technology products, with a core focus on flow cytometry (FCM). Its business model revolves around manufacturing and selling these instruments and associated reagents directly and through distributors.

The company's product portfolio is centered around its flow cytometry systems, designed for both research and clinical applications. Key product lines include the MateCyte™ and LongCyte™ series, which are complemented by auxiliary diagnostic reagents and automated sample preparation instruments. The LongCyte™ flow cytometer, for instance, is a 3-laser, 14-color system that has obtained a Class II medical device registration in China and is approved for the EU market. These systems are engineered to automate and streamline flow technology, featuring capabilities like absolute counting and compatibility with various sample holders, including 96-well plates and tube racks. Challenbio serves a diverse client base that includes clinical diagnosis labs, biotherapy companies, basic biomedical research institutions, and entities involved in drug R&D and food toxicity monitoring. The company reported having nearly 300 users in China and has expanded its sales overseas.

Since its founding, Challenbio has achieved significant milestones, including securing substantial venture capital backing. The company has raised a total of $18.4 million, with a Series B funding round in March 2024 bringing in $13.9 million. Key investors include Addor Capital, Lotus Lake Ventures, and IDG Capital.